Current Cancer Therapy Reviews (Volume 22 - Issue 4)

From Microscopic Survivors to Medical Breakthroughs: Tardigrade Proteins Offer Hope for Safer Cancer Treatments

2026-03-16

Radiation therapy is a cornerstone of cancer treatment, yet its efficacy is often compromised by severe side effects that damage healthy tissues, leading to significant patient discomfort and treatment interruptions. Inspired by the extraordinary resilience of tardigrades, microscopic organisms capable of surviving extreme conditions, researchers have developed a novel approach to mitigate radiation-induced damage. This study focuses on the tardigrade-derived protein Dsup (Damage suppressor), which protects DNA from radiation. By delivering messenger RNA (mRNA) encoding the damage suppressor (Dsup), a DNA-binding protein found in tardigrades, via specialized nanoparticles, scientists have successfully reduced radiation-induced DNA damage in mouse models by up to 50%. The localized and temporary expression of Dsup ensures that healthy tissues are protected without compromising the effectiveness of radiation on tumors. This innovative strategy not only enhances the safety and tolerability of radiation therapy but also holds promise for broader applications, potentially relevant in other high-radiation exposure scenarios, such as chemotherapy or space missions. However, these applications remain to be thoroughly investigated. The research conducted by a collaborative team from MIT, Brigham and Women's Hospital, and the University of Iowa represents a significant advancement in cancer treatment, offering a potential paradigm shift in how we approach radiation damage mitigation. Future efforts will focus on optimizing the delivery system and adapting the Dsup protein for human use, paving the way for clinical trials and real-world applications. This breakthrough underscores the potential of bio-inspired solutions in addressing complex medical challenges.

Reproductive Health and Fertility Preservation Among Cancer Survivors

2026-03-16

Cancer survivorship has been acknowledged as one of the major public health concerns, and this can be attributed to the progress made in the domain of early detection and a wide range of therapeutic options. Cancer treatments, in the form of chemotherapy, radiotherapy, and surgery, can result in a wide range of consequences on the reproductive health of the survivors. Regardless of the documented consequences of cancer treatment on reproductive health, many oncologists and healthcare professionals lack adequate knowledge or competence to discuss fertility risks and prevention approaches with patients. Multiple fertility options can be advised for cancer survivors depending on their age, gender, attainment of puberty, etc. In conclusion, a significant impairment of fertility and reproductive health has been acknowledged among cancer survivors. However, considering the presence of multiple challenges, there is an immense need to integrate fertility preservation into survivorship care, which is inclusive, equitable, and responsive to the needs of survivors.

Chemotherapeutics Associated Central Nervous System Toxicity: Mechanistic Insights

2026-03-16

Introduction: Over the past two decades, cancer has emerged as a major global health concern, affecting a significant portion of the population. While chemotherapeutic agents have revolutionized cancer treatment, they have also introduced a range of adverse effects, with neurotoxicity being a critical complication that can severely limit treatment options.

Objective: This review aims to provide a comprehensive analysis of the mechanisms underlying chemotherapy-induced neurotoxicity and to identify strategies for mitigating its effects.

Method: A comprehensive bibliographic investigation was conducted using scientific databases such as PubMed, Scopus, Web of Science, SciELO, NISCAIR, and Google Scholar. The search included peer-reviewed articles published in English up to December 2024, focusing on the neurotoxic effects of chemotherapy on the central nervous system (CNS). Keywords included “chemotherapy,” “neurotoxicity,” “CNS toxicity,” “oxidative stress,” “neuronal apoptosis,” “hippocampus toxicity,” “cortical toxicity,” “CNS syndromes,” and “neuroinflammation.” Inclusion criteria were studies that reported mechanistic insights, clinical observations, and experimental findings on chemotherapy-induced CNS toxicity. Relevant articles were screened based on title and abstract, followed by a full-text evaluation to extract key data and identify patterns in neurotoxic mechanisms and clinical manifestations.

Results: Patients with underlying conditions such as diabetes, hereditary neuropathies, or previous exposure to neurotoxic agents are particularly susceptible to chemotherapy-induced peripheral and central neurotoxicity. Identified mechanisms include microglial activation, neuronal apoptosis, demyelination, and oxidative stress, especially affecting cortical and hippocampal regions. These processes contribute to cognitive and functional impairments that manifest as transient or progressive neurological symptoms, including cognitive deficits, aphasia, hemiparesis, and dementia. Differentiating these effects from cancer progression remains a clinical challenge and may result in diagnostic delays or treatment errors.

Conclusion: Establishing a clear mechanistic understanding of chemotherapy-induced neurotoxicity is essential for advancing therapeutic strategies that minimize adverse effects. Enhanced knowledge of underlying biological pathways will support the development of neuroprotective interventions and improve patient management outcomes in oncology settings.

Dostarlimab Unveiled: Breakthroughs in Colorectal Cancer Related to Genomic Aberration Coupled with ncRNA Functions

2026-03-16

Introduction: Colorectal cancer (CRC) ranks among the most prevalent malignancies globally, driven by a complex interplay of genetic, molecular, and environmental factors. Dostarlimab, a humanized monoclonal antibody targeting the programmed cell death protein-1 (PD-1) receptor, has emerged as a breakthrough immunotherapy for CRC, particularly in mismatch repair-deficient (dMMR) subtypes. Its ability to enhance anti-tumor immune responses has positioned it as a promising therapeutic agent, with ongoing research exploring its efficacy across CRC subtypes and in combination therapies.

Methods: This study investigates the therapeutic potential of Dostarlimab in CRC management by analyzing scientific data collected from various literature databases, including Google Scholar, Scopus, and PubMed. The review encompasses the genetic and molecular underpinnings of CRC, such as mutations in APC, KRAS, and TP53, and the regulatory roles of non-coding RNAs (ncRNAs). Detailed pharmacological mechanisms, clinical trial outcomes, and comparative efficacy of Dostarlimab against other immunotherapies were evaluated to assess its biological and clinical significance. Analytical aspects of Dostarlimab’s pharmacokinetics and pharmacodynamics were also explored.

Results: Scientific data analysis underscores the pivotal role of Dostarlimab in CRC treatment, particularly for dMMR/MSI-H subtypes, where it achieved a 100% clinical complete response rate in a phase II trial for locally advanced rectal cancer. The drug’s mechanism involves PD-1 inhibition, enhancing T-cell-mediated tumor destruction. Genomic aberrations (e.g., KRAS, BRAF, TP53 mutations) and ncRNAs (e.g., miRNAs and lncRNAs) were identified as key influencers of CRC prognosis and potential therapeutic targets. Dostarlimab exhibits significant efficacy in dMMR/MSI-H CRC, with ongoing trials assessing its impact on mismatch repair-proficient (pMMR) subtypes. Its favorable pharmacokinetic profile (e.g., half-life of 25.4 days) and tolerable safety profile further enhance its clinical utility. Comparative studies with pembrolizumab and nivolumab highlight Dostarlimab’s superior response rates in specific CRC cohorts.

Conclusion: The scientific data from this review affirm the transformative potential of Dostarlimab in CRC management, offering hope for improved outcomes through personalized immunotherapy. Its integration with genetic and molecular insights paves the way for targeted CRC therapies.

A Multi-study Meta-analysis Approach to Identifying Genetic Signatures in Lung Cancer Progression

2026-03-16

Lung neoplasms account for the highest cancer mortality globally. The present study aimed to conduct a preliminary assessment of several studies utilizing sequencing data to examine the genetic profiles of cancer patients and healthy individuals. The findings were analyzed through a meta-analysis approach to identify a shared common gene. The gene of interest was analyzed statistically using selected studies. The BCL2 gene family, with an FDR-P value below 0.01, was selected and identified as a common gene family using the CLC Genomics Workbench 9 software. The BCL2L1 gene was identified as the most significant gene among all the data based on statistical analysis conducted on the isoforms of the BCL2 gene family from each sample using the comprehnsive Meta-Analysis V3 software. The gene involved in the cancer pathway was identified using the KEGG website. In conclusion, the BCL2L1 gene is pivotal in cancer pathogenesis. Hence, by analyzing the gene pathways in which the BCL2L1 gene was implicated and its interactions with other proteins, it can therefore, be considered a potent gene in cancer research.

Research Progress of TRIM56 in Tumours

2026-03-16

Tripartite Motif Containing 56 (TRIM56) is an important member of the TRIM protein family that has gotten a lot of attention because it plays a big part in how tumours start and grow. Research has shown that TRIM56 promotes the growth of various malignancies, such as Cassibian sarcoma, breast cancer, and glioblastoma, and in some types of cancer with specific predisposing factors, such as ovarian cancer and multiple myeloid. It prevents leukaemia, liver cancer, lung adenocarcinoma, and tumours from growing and proliferating cancer cells. Consequently, TRIM56 may regulate tumour proliferation, metastasis, and other processes in both directions. This study aims to explore the dual role of TRIM56 in tumorigenesis and cancer progression. We have outlined its structure, functional domains, and involvement in key signalling pathways, such as the estragon, NF-κB, and TLR3/TTRIF pathways, which are frequently dysregulated in cancer. Furthermore, we investigate TRIM56's regulatory function in the epithelial-mesenchymal transition (EMT) and its differential impacts on tumour proliferation, metastasis, and suppression across various cancers. This review highlights the potential of TRIM56 as a therapeutic target and prognostic biomarker by synthesizing current evidence, emphasizing the need for additional research into its mechanisms and clinical applications. Although TRIM56's function in tumours has been better understood, research is needed to clarify its precise mechanisms in cancer and explore the possibility of using it as a target for therapeutic interventions.

Recent Advancements in Revolutionizing Cancer Therapy with Liposomal Drug Delivery

2026-03-16

Background: The lipid-bilayer liposomes have emerged as promising candidates for the delivery of drugs in cancer treatment due to their capability to protect medications from gastrointestinal degradation, high drug encapsulation efficiency, and the potential for chemical modification through conjugation with various polymers and ligands. These features enhance their physiological properties and improve the therapeutic efficacy of anticancer drugs by enabling more precise tumor targeting. Additionally, Liposomes can potentially enhance the efficacy, durability, and localization of these treatments within the body, offering significant benefits for nanomedicine applications.

Objective: The current review aims to summarize the structural properties of liposomes, the mechanism of action by which liposomes inhibit cancerous cells, and the evolution of liposomal nanomedicine to treat different types of cancers over the last 5 years with patented and marketed formulations.

Methods: A thorough literature review is being carried out with an emphasis on breakthroughs in the production of drug-loaded liposomes between the years 2020-2024, which include tumor cell targeting techniques, liposome surface modification, and multi-drug delivery to enhance therapeutic efficacy.

Results: Recent advancements in liposome technology boosted medication release, tumor accumulation, and tumor targeting without endangering healthy tissues. Poor drug release, restricted penetration into tumor cells, and varying clinical results are still issues.

Conclusion: Liposomes' biocompatibility, ease of synthesis, and capacity to encapsulate both hydrophilic and hydrophobic medications make them versatile choices for drug delivery. Future studies should enhance liposome formulations for large-scale production, explore combination therapies, and tackle regulatory challenges.

Advancements in Cancer Immunotherapy Using CAR T-cells and Vaccines: A Review

2026-03-16

Introduction: Cancer immunotherapy has emerged as a transformative approach to cancer treatment, utilizing the body's immune system to eliminate cancer cells. Key strategies include adoptive cell therapy, which enhances immune cell function, cancer vaccines for cancer prevention, cytokine therapy to modulate immune responses, and oncolytic immunotherapy, which employs engineered viruses to target tumors. This review explores recent therapeutic advancements, developmental strategies, and challenges in cancer immunotherapy over the past five years.

Methods: This review was conducted through a systematic analysis of peer-reviewed literature published between 2019 and 2024 from Web of Science, ScienceDirect, Scopus, PubMed, Google Scholar, and clinical trial databases. The selection criteria included studies on adoptive cell therapy, cancer vaccines, cytokine therapy, oncolytic viruses, and CAR T-cell therapy, focusing on advancements, clinical applications, and associated challenges. Meta-analyses and experimental studies discussing the mechanisms and effectiveness of these therapies were also considered.

Results: Recent findings highlight the remarkable success of CAR T-cell therapy in treating hematologic malignancies, with ongoing research on its application for the treatment of solid tumors. Oncolytic immunotherapy has demonstrated promise by using genetically engineered viruses to enhance immune responses against tumors. Despite these advancements, challenges, such as treatment resistance, toxicity, and high costs, remain obstacles to widespread implementation.

Conclusion: Cancer immunotherapy is reshaping oncology by providing targeted and durable treatment options. The success of CAR T-cell therapy, oncolytic viruses, and cytokine therapy underscores the potential of immune-based approaches. However, issues like immune evasion, treatment-related toxicity, and accessibility must be addressed for optimal outcomes. Future research should focus on improving efficacy, reducing side effects, and expanding accessibility to a broader range of cancers..

Enhancing Cancer Treatment Prognosis through AI-driven Immunotherapy Predictions

2026-03-16

Immune checkpoint inhibitors have become a key component of tumor immunotherapy, which has produced remarkable therapeutic results. Therefore, it is essential to precisely screen patients to understand and predict the treatment's effectiveness. In recent years, in the healthcare profession, the use of Artificial Intelligence has led to a growing body of research suggesting that Artificial Intelligence technology can enhance precision medicine by better anticipating the effectiveness of immunotherapy. This paper highlights the research developments and applications of the existing prediction models, which are based on data from histopathology slides, genomes, and proteomics. In addition, we identified the current obstacles Artificial Intelligence is facing in the field of immunotherapy as well as the future paths that still require improvement. This will serve as a guide for the early adoption of Artificial Intelligence-enabled diagnostic and management systems in the coming years.

Association between Socioeconomic Inequality and the Burden of Stomach Cancer in Asia: Insights from the Global Burden of Disease Study 2021

2026-03-16

Introduction: Stomach cancer represents a significant global health challenge, particularly in Asia, where it is one of the leading causes of cancer-related mortality. This study, analyzing incidence rates, mortality, and disability-adjusted life years (DALYs), explores how socioeconomic factors affect stomach cancer outcomes in various Asian countries.

Methods: The methodology involves a review of publicly available data to estimate the prevalence and mortality associated with stomach cancer in the region. Years of life lost (YLLs) and years lived with disability (YLDs) are calculated specifically to provide a nuanced understanding of the disease burden. The Human Development Index (HDI) serves as a primary measure of socioeconomic status, allowing us to explore how disparities in health outcomes correlate with socioeconomic conditions.

Results: Findings indicate a clear correlation: lower HDI values are associated with higher incidence and mortality rates of stomach cancer. Countries exhibiting greater socioeconomic inequality demonstrate a disproportionate burden of diseases, reflected in elevated DALYs, YLLs, and YLDs.

Discussion: These results underscore the pressing need for targeted public health interventions to address these disparities. Addressing socioeconomic inequalities is crucial for reducing the burden of stomach cancer in Asia. Our findings advocate for implementing strategic public health measures that focus on improving access to healthcare, enhancing nutritional education, and promoting preventive strategies in high-risk populations.

Conclusion: This study contributes to the growing body of evidence linking socioeconomic factors to health disparities and emphasizes the importance of equitable healthcare access in combating stomach cancer effectively.